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Abstract Systemic lupus erythematosus (SLE) patients
exhibit depletion of the intracellular antioxidant glutathi-
one and downstream activation of the metabolic sensor,
mechanistic target of rapamycin (mTOR). Since reversal of
glutathione depletion by the amino acid precursor, N-ace-
tylcysteine (NAC), is therapeutic in SLE, its mechanism of
impact on the metabolome was examined within the con-
text of a double-blind placebo-controlled trial. Quantitative
metabolome profiling of peripheral blood lymphocytes
(PBL) was performed in 36 SLE patients and 42 healthy
controls matched for age, gender, and ethnicity of patients
using mass spectrometry that covers all major metabolic
pathways. mTOR activity was assessed by western blot and
flow cytometry. Metabolome changes in lupus PBL affec-
ted 27 of 80 KEGG pathways at FDR p\ 0.05 with most
prominent impact on the pentose phosphate pathway (PPP).
While cysteine was depleted, cystine, kynurenine, cytosine,
and dCTP were the most increased metabolites. Area
under the receiver operating characteristic curve (AUC)
logistic regression approach identified kynurenine (AUC =
0.859), dCTP (AUC = 0.762), and methionine sulfoxide
(AUC = 0.708), as top predictors of SLE. Kynurenine was
the top predictor of NAC effect in SLE (AUC = 0.851).
NAC treatment significantly reduced kynurenine levels
relative to placebo in vivo (raw p = 2.8 9 10-7, FDR
corrected p = 6.6 9 10-5). Kynurenine stimulated mTOR
activity in healthy control PBL in vitro. Metabolome
changes in lupus PBL reveal a dominant impact on the PPP
that reflect greater demand for nucleotides and oxidative
stress. The PPP-connected and NAC-responsive accumu-
lation of kynurenine and its stimulation of mTOR are
identified as novel metabolic checkpoints in lupus patho-
genesis.
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1 Introduction
Systemic lupus erythematosus (SLE) is a potentially fatal
autoimmune inflammatory disease of unknown etiology.
Dysfunction of T and B cells drives anti-nuclear antibody
production through the release of oxidized immunogenic
nuclear materials from necrotic rather than apoptotic cells
(Perl 2013). Importantly, lupus T cells exhibit mitochon-
drial dysfunction, which is characterized by elevated
mitochondrial transmembrane potential (Dwm) or persistent
mitochondrial hyperpolarization (MHP) that mediates
diminished activation-induced apoptosis and predisposes T
cells to pro-inflammatory death via necrosis (Gergely et al.
2002; Lai et al. 2013). MHP is associated with increased
O2 consumption and electron transport chain activity
(Doherty et al. 2014), promoting the transfer of electrons to
O2, thus resulting in the enhanced production of reactive
oxygen intermediates (ROI), i.e. oxidative stress (Gergely
et al. 2002), and the depletion of reduced glutathione
(GSH) (Gergely et al. 2002). Both GSH depletion (Shah
et al. 2011) and oxidative stress have been confirmed and
implicated in T cells dysfunction in SLE (Li et al. 2014).
In turn, the mechanistic/mammalian target of rapamycin
(mTOR) is a sensor of oxidative stress and regulator of T cell
lineage specification (Chi 2012). As recently documented, N-
acetylcysteine (NAC), a precursor of GSH and antioxidant in
itself, reversed the depletion of GSH, and it also blocked
mTOR activation and improved disease activity in SLE
patients (Lai et al. 2012). However, NAC failed to moderate
MHP and ROI production, suggesting that oxidative stress
may not directly activate mTOR. Although mTOR is widely
recognized as a global sensor and integrator of nutrient path-
ways (Kim et al. 2002), in particular amino acids, the indi-
vidual metabolites have not been identified (Jewell et al.
2013). Here, we document global changes in the metabolome
of peripheral blood lymphocytes (PBL) from SLE patients in
comparison to healthy controls matched at each blood dona-
tion for patients’ age within 10 years, gender, and ethnicity.
Metabolome changes in lupus PBL were most prominently
impacted by the pentose phosphate pathway (PPP). Oxidative
stress was evidenced by the depletion of cysteine and the
increased levels of cystine and methionine sulfoxide (Met-
SO). Area under the receiver operating characteristic (ROC)
curve (AUC) logistic regression approach identified the amino
acid kynurenine (Kyn) to have the greatest specificity and
sensitivity for distinguishing the metabolomes of lupus and
control PBL. NAC treatment reduced Kyn, while it enhanced
NADPH levels in PBL of SLE patients in vivo. Moreover,
Kyn induced mTOR activation in T cells in vitro. This study
thus identifies Kyn accumulation as a potential contributor to
mTOR activation and metabolic target of the therapeutic
action by NAC in patients with SLE.
2 Methods
2.1 Human subjects
36 SLE patients enrolled in double-blind placebo-controlled
treatment trial with N-acetylcysteine (NAC) were investi-
gated. This study has been approved by the Food and Drug
Administration (IND No: 101,320; clinicaltrials.gov identi-
fier: NCT00775476). The clinical trial design, eligibility cri-
teria, randomization, blinding,monitoring of safety, tolerance
and efficacy on NAC in patients with SLE was recently doc-
umented (Lai et al. 2012). SLE disease activity was assessed
using the British Isles Lupus Assessment Group (BILAG)
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(Isenberg et al. 2005) and systemic lupus erythematosus dis-
ease activity index (SLEDAI) (Hochberg 1997). Fatigue was
estimated using the fatigue assessment scale (FAS) (Mich-
ielsen et al. 2003).
The mean (±SEM) age of patients was 44.6 (±1.8) years,
ranging between 25 and64 years, as earlier described (Lai et al.
2012). 34 patients were females including 30 Caucasians, two
African-Americans, and two Hispanic. 2 patients were Cau-
casian males. 42 healthy subjects were individually matched
for eachpatient blooddonation for agewithin ten years, gender,
andethnic backgroundand freshly isolated cellswere studied in
parallel as controls for immunological studies. The mean
(±SEM) age of controls was 44.4 (±1.7) years, ranging
between 22 and 63 years. 39 controls were females including
36 Caucasians, two African-Americans, and one Hispanic. 3
controlswere Caucasianmales. SLE patientswere randomized
to receive either placebo orNAC in one of three treatment arms
of increasing doses: 600, 1,200, or 2,400 mg twice daily for
3 months. 12 patients were enrolled per dosing group, 9
received NACwhile 3 received placebo. For each patient visit,
weobtainedblood fromhealthydonorsmatched for age (within
one decade), gender, and ethnicity, to be used as a control for
flow cytometry measurement of mitochondrial function, gene
expression, andmetabolite analysis. Each patient provided five
blood samples for metabolomic studies (visit 1/pretreatment,
visit 2/after 1 month treatment, visit 3/after 2 months treat-
ment, visit 4/after 3 months treatment, visit 5/after 1 month
washout). 42 healthy controls have also donated blood to use as
control for flow cytometry of live cells as well as for the met-
abolomic, gene expression and signaling studies.
2.2 Metabolyte measurements by LC–MS/MS
5 9 106 monocyte-depleted peripheral blood lymphocytes
(PBL) were washed in PBS, resuspended in 100 ll of 80 %
methanol (-80 C). After freezing at -80 C and thawing
once, the sample was centrifuged at 13,000 x g for 30 min at
4 C, and 100 ll of supernatant was saved. A 2nd 100 ll of
80 % methanol (-80 C) was added to the pellet, the sample
was vortexed, centrifuged at 13,0009g for 30 min at 4 C,
and the 2nd 100 ll of supernatant was saved. The two 100-ll
supernatants were combined, dried in a SpeedVac (Savant
AS160, Farmingdale, NY), and stored-80 C until analysis.
Each sample was resuspended in 20 ll of LC/MS grade water
and 10 ll per sample was injected into a 5500 QTRAP, a
hybrid triple quadrupole/linear ion trap mass spectrometer,
using a quantitative polar metabolomics profiling platform
with selected reactionmonitoring (SRM) that covers allmajor
metabolic pathways. The platform uses hydrophilic interac-
tion liquid chromatography with positive/negative ion
switching to analyze 258 metabolites (289 Q1/Q3 transitions)
from a single 15-min targeted liquid chromatography–tandem
mass spectrometry (LC–MS/MS) acquisition with a 3-ms
dwell time and a 1.55-s duty cycle time (Yuan et al. 2012).
A healthy subject matched for age within 10 years,
gender, and ethnicity was recruited upon each patient visit.
The blood samples of patients and matched controls were
processed in parallel on ice, stored in parallel at -80 C
until injected in the same run for LC–MS/MS analysis.
2.3 Metabolic pathway and statistical analyses
Quantitative enrichment analysis of 258 detected metabolites
was utilized for pathway analysis employing the web-based
MetaboAnalyst 2.0 software (Xia and Wishart 2011). Upon
each patient visit, a healthy subject matched for age within
10 years, gender, and ethnicity was recruited. The blood
samples were processed in parallel. The patients and matched
healthy subjects were injected in the same run. The signal
stability was assured by normalizing the controls between runs
to the sum of all signals between separate runs using Metab-
oanalyst (Xia andWishart 2011). The enrichment analysiswas
based on global analysis of covariance (Ancova). A Google-
map style interactive visualization systemwas utilized for data
exploration and creation of a 3-level graphical output: me-
tabolome view, pathway view, and compound view. The
‘metabolome view’ shows all metabolic pathways arranged
according to the scores from enrichment analysis (y axis:-log
p) and from topology analysis (x axis: impact: number of
detectedmetaboliteswith significant p value) (Xia andWishart
2011). The matched metabolites are highlighted according to
their Holm p values. The Holm p is the p value adjusted by
Holm-Bonferroni method (Holm 1979). The pathway topol-
ogy analysis used two well-established node centrality mea-
sures to estimate node importance: degree centrality and
betweeness centrality. Degree centrality depends on the
number of links connected to a given node. For directed
pathway graphs, there are two types of degrees: in-degree for
links came from other nodes, and out-degree for links initiated
fromthe current node.Here,weonly considered the out-degree
for node importance measure. Upstream nodes are considered
to have regulatory roles for the downstreamnodes, and not vice
versa. The betweeness centrality measures the number of
shortest paths going through the node. Since metabolic net-
works are directed, we use relative-betweeness centrality for a
metabolite importance measure (Tuikkala et al. 2012). The
degree centrality measures focus more on local connectivities,
while the betweeness centralitymeasures focusmore on global
network topology. The node importance values calculated
from centrality measures were further normalized by the sum
of the importance of the pathway. Therefore, the total/maxi-
mum importance of each pathway reflects the importance
measure of eachmetabolite node that is actually the percentage
relative to the total pathway importance, and the pathway
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impact value is the cumulative percentage from the matched
metabolite nodes. The altered compounds have been grouped
and presented together for each pathway.
The impact of NAC on metabolic changes relative to pla-
cebo was investigated by performing a two-factor (NAC
versus placebo) time series analysis (changes relative to
baseline/visit 1) within individual subjects. Two-way within-
subject ANOVA was performed, and the interaction of drug
with time was analyzed by comparing data acquired after
treatment for 1 month (visit 2), 2 months (visit 3), and
3 months (visit 4) relative to baseline (visit 1). Using Me-
taboAnalyst, we also performed ANOVA-simultaneous
component analysis (ASCA), which is a multivariate exten-
sion of ANOVA. It is designed to identify the major patterns
associatedwith each factor. This implementation supports the
ASCA model for two factors with one interaction effect. The
algorithm first partitions the overall data variance (X) into
individual variances induced by each factor (A and B), aswell
as by the interactions (AB). The formula is shown belowwith
(E) indicates the residual Errors: X = A ? B ? AB ? E.
The SCA part applies principal component analysis (PCA) to
A,B, AB to summarizemajor variations in each partition. The
significant variables are identified based on the leverage and
the squared prediction errors (SPE) associated with each
variables. Variables with low SPE and higher leverage are
modeled well after the major patterns. Pre-treatment samples
obtained at visit 1 were also compared to samples obtained at
visits 2–4 during biologically and clinical effective adminis-
tration of NAC at doses of 2.4 and 4.8 g/day by ANCOVA.
Metabolite concentrations were evaluated for their
ability to discriminate between SLE and control subjects by
partial least squares-discriminant analysis (PLS-DA) using
MetaboAnalyst (Xia and Wishart 2011). PLS is a super-
vised method that uses a multi-variate regression technique
to extract via linear combination of metabolites (X) the
information that can predict the subject group membership
(Y). The classification and cross validation were performed
using the wrapper function offered by the caret package in
MetaboAnalyst software (Xia and Wishart 2011). In order
to assess that the class discrimination is statistically sig-
nificant, a permutation test was performed. In each per-
mutation, a PLS-DA model was built between the data
(X) and the permuted class labels (Y) using the optimal
number of components determined by cross validation for
the model based on the original class assignment. The ratio
of the between sum of the squares and the within sum of
squares (B/W-ratio) for the class assignment prediction of
each model was calculated. PLS-DA models were vali-
dated by permutation test p value\0.05. Contribution of
individual metabolites to PLS-DA was assessed by variable
importance in projection (VIP) and coefficient scores.
Individual compounds were also compared between
control and lupus PBL by paired or unpaired t-test with
Welch’s correction using Prism software (GraphPad, San
Diego, CA). Pearson’s correlations of normalized metab-
olite concentrations with disease activity and flow cytom-
etry parameters were determined with MetaboAnalyst and
Prism. Areas under the receiver operating characteristic
(ROC) curve (AUC) logistic regression approach was used
for evaluating the specificity and sensitivity of individual
metabolites and metabolite ratios for distinguishing lupus
and control PBL as well as NAC-treated and untreated
lupus PBL.
2.4 Western blot analyses
Whole cell protein lysates were prepared by lysis in radio-
immunoprecipitation assay buffer (150 mM NaCl, 2 % NP-
40, 0.5 % sodium deoxycholate, 0.1 % SDS, 50 mMTris pH
8.0, 1 mM PMSF, 1 lg/ml aproptinin, 1 lg/ml pepstatin,
1 lg/ml leupeptin, 1 mMNaF, 1 mM sodium orthovanadate,
0.1 mM sodium molybdate, 10 mM sodium pyrophosphate)
at a density of 4 9 107 cells/ml on ice, followedby addition of
equal volumes of Laemmli protein sample buffer (60 mM
Tris–Cl pH 6.8, 2 % SDS, 10 % glycerol, 5 % b-mercap-
toethanol, 0.01 % bromophenol blue) and heated to 95 C for
5 min prior to separation on SDS-PAGE gels and transfer to
0.45 lm nitrocellulose membranes. 4E-BP1 (4E-BP1; Cat no
9644) and phospho-4E-BP1 (p4E-BP1 Thr 37/46, Cat no
2855) antibodies were obtained from Cell Signaling. p70 S6
kinase (S6 K, Cat no sc-8418) and phospho-p70 S6 kinase
(pS6K Thr 389, Cat no sc-8416) were from Santa Cruz Bio-
technology. Reactivity to primary antibodies was detected
with horseradish peroxidase-conjugated secondary antibodies
(Jackson, West Grove, PA) and visualized by enhanced
chemiluminescence (Western Lightning Chemiluminescence
Reagent Plus, GE Health Care/PerkinElmer Life Sciences,
Inc., Boston, Massachusetts). Automated densitometry was
used to quantify the levels of mTOR substrate protein
expression relative to b-actin using a Kodak Image Station
440CF with Kodak 1D Image Analysis Software (Eastman
Kodak Company, Rochester, NY).
2.5 Flow cytometry detection of mTOR activity
PBL from eight healthy subjects were incubated with kyn-
urenine (Kyn, 0.05, 0.1, 0.5, and 1), L-homocysteic acid
(HCA, 100, 500 lM, 1 mM, 5 mM) and dibutyryl cAMP
(db-cAMP, 500 lM) for 24 h. Tryptophan was used as a
control amino acid (100 lM, 1 mM, 10 mM). All chemicals
were obtained from Sigma (St. Louis, MO).The effect of
these metabolites on mTOR activity was measured via
phosphorylation S6RP (Lai et al. 2012). T-cell subsets were
analyzed by staining with antibodies to CD4, CD8, and
CD25. For detection of mTOR activity and FoxP3 expres-
sion, cells were permeabilized with Cytofix/CytopermPlus
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(eBiosciences) and stained with AlexaFluor-488-conjugated
antibody to pS6RP (Cell Signaling; Beverly, MA; Cat. No.
4851) and AlexaFluor-647-conjugated antibody to FoxP3
(BioLegend, San Diego, CA; Cat No 320014), as earlier
described (Lai et al. 2012).
3 Results
3.1 Metabolome analysis reveals dominant impact
of SLE on the pentose phosphate pathway,
nucleotide, cysteine, and kynurenine metabolism
Quantitative enrichment analysis of 258 measured metabo-
lites revealed robust changes in the metabolome of SLE
patients’ PBL relative to those of healthy controls matched
for age within 10 years, gender, and ethnic background. The
metabolome changes affected 27 of 80 pathways in the
KEGG database at false discovery rate (FDR) p value\0.05,
with the most prominent impact on the pentose phosphate
pathway (PPP, Fig. 1a, Fig. S1 and Table 1). The pathway
changes were driven by the accumulation of 32 among 34
metabolites altered in lupus PBL (Fig. 1b) 0.11 of these
metabolites are involved in multiple pathways, with 4/11
being substrates in the PPP (Fig. 1b). After the PPP, gly-
colysis, starch (carbohydrate), taurine, as well as purine and
pyrimidine metabolism were the most affected pathways
(Table 1). Only 2 metabolites were depleted, cysteine and
inosine. Cysteine is a substrate of 6 pathways affected by
SLE: GSH, taurine, thiamine, Gly-Ser-Thr, Cys-Met, and
sulfur metabolism (Fig. S1). Moreover, we also observed the
accumulation of kynurenine (Kyn), which is a product of
Fig. 1 Metabolic pathway analysis of quantitative changes in com-
pound concentrations in PBL samples of 36 SLE patients relative to 42
healthy subjects matched for age within 10 years, gender, and ethnic
background. a The ‘metabolome view’ shows all 80 KEGG metabolic
pathways arranged according to the scores from enrichment analysis
(y axis: -log p) and topology analysis (x axis: impact: number of
detected metabolites in a pathway with significant p values). bMetab-
olites with altered levels in lupus PBL relative to matched healthy
control PBL normalized to 1.0 for each compound. 6 of 34 altered
metabolites can enter multiple pathways: 4 of such 6 metabolites are
substrates in the PPP, while 2 metabolites are common with the TCA.
Only 2/34 altered metabolites were depleted, cysteine and inosine
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tryptophan catabolism (Aune and Pogue 1989) and regulator
of the PPP (Fabregat et al. 1987).
Partial least squares-discriminant analysis (PLS-DA) of
metabolite concentrations discriminated between lupus and
control PBL (Fig. 2a), as validated by permutation test p
value\ 0.001 (Fig. 2b).Three component matrices accoun-
ted for 20.2, 6.9, and 4.5 % of the total variance (Fig. 2a).
Top contributors to the PLS-DA included nucleotides and
their amino acid and PPP sugar precursors. Individually,
cytosine, dCTP, guanosine, cystine, and Kyn were the most
increased while cysteine was the most depleted metabolite in
lupus PBL (Fig. 2c).These metabolites were the greatest
contributors to PLS-DA components 1–3 based on both
variable importance in projection (VIP) (Fig. 2d) and coef-
ficient scores (Fig. 2e). The pyrimidine nucleotide cytosine,
dCTP, and Kyn had the top VIP and coefficient scores
(Fig. 2d, e). Although methanol extraction, which was uti-
lized to process cell extracts for LC–MS/MS studies, was
not sensitive for detection of GSH, oxidative stress was
evidenced by the depletion of cysteine and the accumulation
of cystine and Met-SO (Fig. 1b, c). Correlation analysis with
metabolites exhibiting dominant changes between lupus and
control PBL (Fig. 2c) unveiled additional trends of oxidative
stress, such as positive correlations of cysteine with ascor-
bate, GSH, and GSH/GSSG ratio (Fig. 2f).
Area under the receiver operating characteristic (ROC)
curve (AUC) logistic regression approach identified Kyn
(AUC= 0.859), dCTP (AUC = 0.762), andMet-SO (AUC =
0.708) to have the greatest specificity and sensitivity for dis-
tinguishing themetabolomesof lupus andcontrolPBL(Fig. 3).
3.2 Correlation of metabolite concentrations
with disease activity
Concentrations of 18, 16, and 32 compounds showed
significant correlation at FDR p\ 0.05 with SLEDAI
(Table 2), BILAG (Table 3), and FAS disease activity
scores in 36 SLE patients unexposed to NAC (Table 4),
Table 1 Metabolome effects of lupus by quantitative enrichment analysis of 209 metabolites in PBL of SLE patients in comparison to those of
healthy controls matched for age within 10 years, gender, and ethnic background
Total Hits Raw p -LOG (p) FDR p Impact
Pentose phosphate pathway (PPP) 32 14 0.0097581 4.6297 0.022621 0.58698
Glycolysis 31 11 0.0005255 7.5511 0.005361 0.39538
Taurine and hypotaurine 20 4 0.007702 4.8663 0.019756 0.39131
Starch and sucrose 50 7 0.0070929 4.9487 0.019756 0.36587
Purine metabolism 92 20 0.0050401 5.2903 0.01512 0.34287
Pyrimidine metabolism 60 10 3.73E-07 14.8 1.90E-05 0.2062
Phenylalanine, tyrosine and tryptophan biosynthesis 27 7 0.0081346 4.8116 0.019756 0.19356
Citrate cycle (TCA cycle) 20 5 0.0008794 7.0362 0.007475 0.1875
Glyoxylate and dicarboxylate metabolism 50 5 0.0013318 6.6212 0.008382 0.15152
Cysteine and methionine metabolism 56 5 0.0018078 6.3156 0.008382 0.14815
Arginine and proline metabolism 77 7 0.0017812 6.3305 0.008382 0.14563
Nicotinate and nicotinamide metabolism 44 4 0.0027461 5.8976 0.01009 0.14545
Glutathione metabolism 38 6 0.022229 3.8064 0.043602 0.14517
Alanine, aspartate and glutamate metabolism 24 3 0.015304 4.1797 0.03252 0.14286
Pyruvate metabolism 32 6 9.36E-06 11.579 0.000239 0.14035
Galactose metabolism 41 6 0.0004329 7.745 0.005361 0.13792
Glycine, serine and threonine metabolism 48 8 0.0014171 6.5591 0.008382 0.1356
Nitrogen metabolism 39 7 0.017404 4.0511 0.035504 0.13461
Phenylalanine metabolism 45 3 0.024612 3.7045 0.045465 0.12727
Glycerophospholipid metabolism 39 4 0.0015563 6.4654 0.008382 0.12329
Pantothenate and CoA biosynthesis 27 4 0.024961 3.6904 0.045465 0.12121
Glycerolipid metabolism 32 5 0.0004521 7.7015 0.005361 0.08888
Fructose and mannose metabolism 48 4 0.0042946 5.4504 0.014602 0.08197
Sulfur metabolism 18 3 0.0047212 5.3557 0.015049 0.07407
Tryptophan metabolism 79 2 0.0077869 4.8553 0.019756 0.07142
Thiamine metabolism 24 2 0.01435 4.244 0.031819 0.06896
Pentose and glucuronate interconversions 53 5 0.0024615 6.007 0.01009 0.05001
The metabolome changes affected 27 of 80 pathways in the KEGG database at false discovery rate (FDR) p value\0.05. The pathways are
arranged by the relative impact of the number of metabolites affected and their node of importance (Xia et al. 2012)
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respectively. 9 compounds showed correlation with all
three disease activity scores: dihydroxy-acetone-phosphate
(DHAP), oxaloacetate (OAA), glucose 1-phosphate (G1P),
hexose-phosphate, deoxyribose-phosphate, uracil, aceto-
acetate, geranyl pyrophosphate (GPP), and indole-3-car-
boxylic acid. DHAP connects the PPP while OAA
connects the TCA with glycolysis. Glucose-1-phosphate is
generated during glycogenolysis. It can be converted into
G6P for metabolism through the PPP or glycolysis (Mayes
1993). Hexose-phosphate and deoxyribose-phosphate
represent structural isomers of compounds that are
involved in the PPP, glycolysis, and nucleotide metabo-
lism. Acetoacetate is the product of amino acid and fatty
acid catabolism. GPP is an intermediate towards the
biosynthesis of farnesyl pyrophosphate, geranylgeranyl
pyrophosphate, and cholesterol (Holstein and Hohl 2004).
Rab GTPases require geranylgeranyl pyrophosphate to
attach to endosomes and to regulate endosome traffic,
which is increased in lupus T cells (Fernandez et al.
2009).
3.3 Kynurenine accumulation is most prominently
reversed by NAC treatment in vivo
As previously shown, GSH is depleted in lupus PBL
(Gergely et al. 2002) and its reversal by treatment with
Fig. 2 Partial least squares-discriminant analysis (PLS-DA) of
metabolite concentrations in lupus and control PBL. Samples
obtained from 36 lupus patients before initiation of treatment with
NAC, e.g. Visit 1, were compared to samples from 42 healthy
subjects processed in parallel. a 3-dimensional score plot of PLS-DA
using components 1, 2, and 3, accounting for 20.2, 6.9, and 4.5 % of
the total variance. b Validation of PLS-DA by permutation test p
value\0.001. c Volcano plot is a combination of fold change (FC,
log2 FC: X axis) and t test p values (-log10 p: Y axis). d Variable
importance in projection (VIP) scores of 15 top contributors to PLS-
DA components 1–3. e Coefficient-based importance measures of top
15 contributors to components 1–3. f Correlation plot showing the
compounds as horizontal bars, with colors in light pink indicating
positive correlations and those in light blue indicating negative
correlations with top lupus-associated metabolites identified in the
volcano plot (c). Values reflect Pearson’s correlation coefficients
between metabolite concentrations at FDR p\ 0.05 calculated by
MetaboAnalyst (Color figure online)
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Fig. 3 Discrimination of the
metabolome of lupus and
control PBL based on area
under the receiver operating
characteristic (ROC) curve
(AUC) logistic regression
approach. For each of the top
three discriminating
metabolites, the left panel
shows the AUC confidence
interval, true positive and false
positive rates, and confidence
interval (CI), the right panel
shows the concentrations of
metabolites in PBL before
(baseline) and during NAC
treatment (NAC). AUC logistic
regression approach identified
Kyn (AUC = 0.859), dCTP
(AUC = 0.762), and Met-SO
(AUC = 0.708) to have the
greatest specificity and
sensitivity for distinguishing the
metabolome of lupus and
control PBL
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NAC was safe and effective in reducing disease activity in
patients with SLE (Lai et al. 2012). Therefore, we inves-
tigated the metabolomic impact of NAC relative to placebo
by performing a two-factor (NAC versus placebo) time
series analysis within individual subjects using samples
acquired during the randomized double-blind clinical trial
(Lai et al. 2012). Two-way within-subject ANOVA was
performed and the interaction of drug with time was ana-
lyzed by comparing data acquired after treatment for
1 month (visit 2), 2 months (visit 3), and 3 months (visit 4)
relative to baseline (visit 1). Following Bonferroni’s cor-
rection for 197 detected metabolites, NAC treatment sig-
nificantly reduced Kyn levels relative to placebo (raw
p = 2.8 9 10-7, FDR corrected p = 6.6 9 10-5). 10
Table 2 Correlation of
metabolite concentrations with
SLEDAI in PBL of 36 lupus
patients that have not been
exposed to NAC
Compounds in italics correlated
at FDR p\ 0.05 with SLE,
BILAG, and FAS scores
Correlation t-stat p value FDR
SLEDAI 1 Inf 0 0
BILAG 0.77074 8.8892 3.72E-12 4.41E-10
DHAP 0.53154 4.6114 2.49E-05 0.00197
Hexose-phosphate 0.49239 4.1572 0.000116 0.005688
Betaine 0.49144 4.1466 0.00012 0.005688
Oxaloacetate 0.48506 4.076 0.000151 0.00598
Deoxyribose-phosphate 0.47252 3.9399 0.000236 0.007987
G1P 0.46369 3.8459 0.000319 0.009455
2-oxobutanoate 0.45647 3.7701 0.000406 0.010696
Acetoacetate 0.4289 3.4889 0.000973 0.023066
Acetylphosphate 0.41531 3.3549 0.001458 0.031419
P-hydroxybenzoate 0.40933 3.2968 0.001733 0.034228
1,3-diphopshateglycerate 0.4024 3.2301 0.002109 0.038445
Uracil 0.39868 3.1945 0.002339 0.03907
UDP-N-acetyl-glucosamine -0.39667 -3.1754 0.002473 0.03907
Spermine 0.38916 3.1045 0.003033 0.044928
GPP 0.38612 3.076 0.00329 0.045871
7-methylguanosine -0.38033 -3.0219 0.003835 0.048726
Xanthine 0.37934 3.0128 0.003935 0.048726
Indole-3-carboxylic acid 0.37765 2.9971 0.004112 0.048726
Table 3 Correlation of
metabolite concentrations with
BILAG in PBL of 36 lupus
patients that have not been
exposed to NAC
Compounds in italics correlated
at FDR p\ 0.05 with SLE,
BILAG, and FAS scores
Correlation t-stat p value FDR
BILAG 1 Inf 0 0
SLEDAI 0.77074 8.8892 3.72E-12 4.41E-10
Acetylphosphate 0.52377 4.5183 3.43E-05 0.002459
Deoxyribose-phosphate 0.51909 4.4628 4.15E-05 0.002459
Hexose-phosphate 0.5006 4.2495 8.52E-05 0.004041
NADP 0.48776 4.1058 0.000137 0.005423
GPP 0.47847 4.0041 0.000192 0.005973
Uracil 0.47702 3.9884 0.000202 0.005973
G1P 0.46738 3.8849 0.000282 0.00722
DHAP 0.46433 3.8527 0.000312 0.00722
Flavone 0.46118 3.8194 0.000347 0.00722
Pyrophosphate 0.45965 3.8033 0.000366 0.00722
Indole-3-carboxylic acid 0.4546 3.7505 0.000432 0.007877
Acetoacetate 0.40659 3.2703 0.001874 0.029561
Glycolate 0.40395 3.245 0.002019 0.029561
Asparagine -0.40296 -3.2354 0.002076 0.029561
Oxaloacetate 0.4022 3.2282 0.00212 0.029561
dATP -0.39857 -3.1935 0.002346 0.03089
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Table 4 Correlation of
metabolite concentrations with
FAS fatigue scores in PBL of 36
lupus patients that have not been
exposed to NAC
Compounds in italics correlated
at FDR p\ 0.05 with SLE,
BILAG, and FAS scores
Correlation t-stat p value FDR
FAS 1 3.49E?08 0 0
SLEDAI 0.69858 7.1744 2.15E-09 2.56E-07
BILAG 0.61666 5.7563 4.18E-07 3.33E-05
Dihydroxy-acetone-phosphate 0.59713 5.4703 1.19E-06 7.09E-05
Oxaloacetate 0.57832 5.2093 3.04E-06 0.000145
Acetoacetate 0.57098 5.1108 4.32E-06 0.000172
Flavone 0.56337 5.0108 6.17E-06 0.000211
2,3-Diphosphoglyceric acid 0.53154 4.6113 2.49E-05 0.000745
Indole-3-carboxylic acid 0.52839 4.5735 2.84E-05 0.000755
Quinolinate 0.52241 4.5021 3.63E-05 0.000853
1,3-diphopshateglycerate 0.52046 4.4791 3.93E-05 0.000853
Phosphoenolpyruvate 0.50927 4.3485 6.11E-05 0.001218
Deoxyribose-phosphate 0.50568 4.3073 7.02E-05 0.001291
UDP-N-acetyl-glucosamine -0.48004 -4.0211 0.000181 0.003093
Uracil 0.47805 3.9995 0.000194 0.003098
Acetylcarnitine DL 0.4659 3.8692 0.000296 0.004424
Betaine 0.45695 3.7751 0.0004 0.00562
Glucose-1-phosphate 0.45371 3.7413 0.000445 0.005907
Pyrophosphate 0.44728 3.6749 0.000548 0.006894
Citraconic acid 0.44003 3.6009 0.00069 0.008244
Gpp 0.43595 3.5597 0.000784 0.008919
Methionine -0.43294 -3.5293 0.00086 0.009345
Damp -0.41094 -3.3124 0.001655 0.017196
Kynurenic acid 0.40727 3.2769 0.001838 0.018304
Glucosamine 0.40158 3.2223 0.002157 0.020269
2-oxobutanoate 0.4008 3.2148 0.002205 0.020269
Hydroxyphenylacetic acid 0.39148 3.1263 0.002849 0.025185
P-hydroxybenzoate 0.39019 3.1141 0.002951 0.025185
Hexose-phosphate 0.38844 3.0977 0.003092 0.025486
Asparagine -0.37362 -2.9599 0.004563 0.036352
Shikimate 3-phosphate 0.36996 2.9263 0.005009 0.038619
Nicotinate 0.36814 2.9096 0.005246 0.038923
Coenzyme A -0.36718 -2.9008 0.005374 0.038923
Kyn 0.36418 2.8735 0.005794 0.040726
A-ketoglutarate 0.35619 2.8012 0.007053 0.048159
Table 5 Effect of NAC relative
to placebo by two-way ANOVA
using time series (relative to
visit 1) with drug interaction
(NAC versus Placebo)
Only Kyn (in italics) survived
Bonferroni’s correction for 197
detected metabolites
FDR p Time Drug Interaction
Kyn 0.66378 0.85943 2.88E-07
6-Phospho-D-gluconate 0.48715 0.39983 0.001036
Purine 0.00876 0.20384 0.010943
Coenzyme A 0.23545 0.57885 0.011679
Pyroglutamic acid 0.22904 0.48637 0.014384
Orotate 0.20237 0.11511 0.021869
Betaine aldehyde 0.41832 0.73716 0.027097
Glucosamine 0.2869 0.54004 0.031178
5-Phosphoribosyl-1-pyrophosphate 0.11376 0.83987 0.034412
N-Acetyl-glucosamine 0.89918 0.55091 0.034934
2-Deoxyglucose-6-phosphate 0.46704 0.68485 0.038873
Flavone 0.46578 0.44401 0.049396
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additional metabolites, were affected by NAC with raw
p\ 0.05 (Table 5), including mTOR-regulated orotate
(Ben-Sahra et al. 2013). A multivariate extension of
ANOVA, ASCA identified nine metabolites, also including
Kyn as the top compound that best modeled the interaction
between time and drug (Table 6).
The impact of NAC on the metabolome of lupus PBL was
further evaluated by pathway analysis comparing pre-treat-
ment samples obtained at visit 1 to samples obtained at visits
2–4 during biologically and clinical effective administration
of NAC at doses of 2.4 and 4.8 g/day. In contrast to the robust
differences between the global metabolomes of lupus and
control PBL at baseline, NAC treatment affected a narrow
range of metabolites (Fig. 4a) without global effect on the
metabolome (Fig. 5a). As shown in Fig. 4a, NAC treat-
ment markedly increased NADPH (?281 ± 57 %, p =
0.035),while it diminished Kyn (-55 ± 16 %, p = 0.04),
HCA (-66 ± 7 %, p = 0.0008), N-acetyl-glutamine





Coenzyme A 0.067726 3.532872
dUTP 0.060871 0.666888





The significant variables have been identified based on the leverage
and the Squared Prediction Errors (SPE) associated with each vari-
able. Variables with low SPE and higher leverage modeled well after
the major patterns: time, drug, and interaction of time and drug. The
table shows metabolites that modeled well by interaction effect
between Time and Drug
Fig. 4 Effect of in vivoNAC treatment onmetabolite concentrations in
lupus PBL by comparing pre-treatment samples obtained at visit 1 to
samples obtained at visits 2–4 during biologically and clinical effective
administration ofNACat doses of 2.4 g/day and4.8 g/day.aMetabolite
concentrations affected by NAC at p\ 0.05 on the basis of ANOVA.
b 3-dimensional score plot of PLS-DA with components 1, 2, and 3,
accounting for 18.9, 5.8, and 4.3 % of the total variance. cValidation of
PLS-DA by permutation test p = 0.007. d Volcano plot is a combi-
nation of fold change (log2 FC: X axis) and t test p values (-log10 p: Y
axis). e Variable importance in projection (VIP) scores of 15 top
contributors to the PLS-DA components 1–3. f Coefficient-based
importance measures of the top 15 contributors to components 1–3.
g Correlation plots showing the compounds as horizontal bars, with
colors in light pink indicating positive correlations and light blue
indicating negative correlations with top lupus-associated metabolites
identified in the volcano plot (d). Values reflect Pearson’s correlation
coefficients between metabolite concentrations at FDR p\ 0.05
calculated by MetaboAnalyst (Color figure online)
Metabolome of SLE 1167
123
(-37 ± 7 %, p = 0.015), succinic acid (-34 ± 6 %,
p = 0.025), cytidine (-50 ± 9 %, p = 0.027), hypoxan-
thine (-45 ± 10 %, p = 0.032), cAMP (-58 ± 6 %,
p = 0.033), methyl-malonic acid (-33 ± 7 %, p = 0.035),
acetyl-coenzyme A (-27 ± 4 %, p = 0.044), flavone
(-46 ± 11 %, p = 0.045), and CDP-choline (-28 ± 7 %,
p = 0.048). At 95 % confidence interval (CI), the effects of
NAC treatment on Kyn, HCA, and NADPH were also sig-
nificant (data not shown). Pathway analysis only showed an
influence on tryptophan metabolism, mainly through Kyn,
xanthurenic acid, and Ac-CoA, and lesser effects on GSH
metabolismand fatty acid elongation inmitochondria; noneof
these pathway effects survived FDR correction (Fig. 5b).
PLS-DA of metabolite concentrations effectively dis-
criminated between baseline and NAC-treated lupus PBL
(Fig. 3b), as validated by permutation test p = 0.007
(Fig. 4c).NAC decreased Kyn, HCA, deoxyinosine, and
cAMP and increased NADPH, as shown by Volcano plot
(Fig. 4d). NADPH, HCA, and Kyn had the greatest PLS-DA
VIP (Fig. 4e) and coefficient scores towards distinguishing
lupus PBL obtained before treatment from lupus PBL
obtained during NAC treatment (Fig. 4f). Pearson’s correla-
tion analysis with top PLS-DA coefficients revealed signifi-
cant interconnectedness among pathways represented by
lupus-associated metabolites (Fig. 4g). Thus, NADPH nega-
tively correlated with sedoheptulose 1,7-bisphosphate (SBP,
r = -0.51; FDR p = 0.033) and HCA (r = -0.49; FDR
p = 0.035). Kyn significantly correlated with 22 metabolites
at FDR\0.05, dominated by purine nucleotides such as GDP
(r = 0.58; FDR p = 0.003). HCA positively correlated with
49 metabolites at FDR p\ 0.05, including sedoheptulose
7-phosphate (S7P; r = 0.43; p = 0.028), inositol (r = 0.41;
p = 0.035), carbamoyl phosphate (r = 0.40; p = 0.036).
cAMPcorrelatedwith taurine (r = 0.58; FDRp = 0.003) and
48 other metabolites, including GPP (r = 0.57; FDR
p = 0.003), CDP-choline (r = 0.57; FDR p = 0.003), ky-
nurenic acid (r = 0.56; FDRp = 0.003), 1-methyl-adenosine
(r = 0.49; FDR p = 0.012), carbamoyl phosphate (r = 0.48;
FDR p = 0.016), deoxyinosine (r = 0.47; FDR p = 0.016),
inositol (r = 0.47; FDR p = 0.016), dihydroorotate
Fig. 5 Effect of NAC on the metabolome of lupus PBL. a Global
metabolome and pathway analyses were performed between 15 pre-
treatment samples obtained at visit 1 and 29 samples obtained at visits
2–4 during biologically and clinical effective administration of NAC
at doses of 2.4 g/day in 17 patients and 4.8 g/day in 12 patients.
b Effect of NAC on metabolic pathways. 3 pathways were affected by
NAC treatment, tryptophan, GSH, and mitochondrial fatty acid
elongation (mFA); none of these pathway effects survived FDR or
Bonferroni correction
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Fig. 6 Receiver operating
characteristic (ROC) curve
logistic regression analysis of
the metabolomic effects by
NAC in lupus PBL. For each of
the top three metabolites, the
left panel shows the area under
the ROC curve (AUC), true
positive and false positive rates,
and confidence interval (CI), the
right panel shows the
concentrations of metabolites in
PBL before (baseline) and
during NAC treatment (NAC).
AUC logistic regression
analysis indicated that Kyn
(AUC = 0.851), NADPH
(AUC = 0.752), and cAMP had
the greatest specificity and
sensitivity to detect the
metabolomic effects of NAC in
SLE (AUC = 0.723)
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(r = 0.45; FDR p = 0.019), and NADP (r = 0.43; FDR
p = 0.025). Deoxyinosine correlated with cAMP (r = 0.52;
FDR p = 0.021), NADH (r = 0.52; FDR p = 0.021), and
Kyn (r = 0.45; FDR p = 0.052). These latter findings are
consistent with the involvement of Kyn in nucleotide metab-
olism (Pileni et al. 1977). AUC logistic regression analysis
indicated that Kyn (Fig. 6a), NADPH (Fig. 6b), and cAMP
had the greatest specificity and sensitivity to detect the met-
abolomic effects of NAC in SLE (Fig. 6c).
3.4 Kynurenine stimulates mTOR activity in DN T
cells
Treatment of SLE patients with NAC resulted in the reversal
of mTOR activation in T cells, most prominently in
CD4-CD8- double-negative (DN) T cells (Lai et al. 2012).
These DN T cells have been implicated in elevated pro-
duction of IL-4 (Chan et al. 2006) and IL-17 (Kato and Perl
2014) and stimulating anti-DNA production (Shivakumar
et al. 1989) and organ damage (Crispin et al. 2008). There-
fore, we examined whether the metabolites that were found
to be accumulated in lupus PBL and regulated by treatment
with NAC (Kyn, HCA, and cAMP), were actually capable of
activating mTOR. Among these metabolites, only kynu-
renine activated mTOR complex 1 activity, as measured by
phosphorylation of 4E-BP1, both in the Jurkat human T cell
line and primary PBL (Fig. 7a, b). The effect of these
metabolites on mTORC1 activity within T-cell subsets was
measured via phosphorylation S6RP (Lai et al. 2012). T-cell







































































































Fig. 7 Activation of mTOR by kynurenine (Kyn). a Jurkat human T
cells were incubated with or without Kyn at the indicated concen-
trations of 0.5 and 1 mM for 24 h and analyzed by western blot.
mTORC1 activity was assessed by the levels of phosphorylated
substrates, p4E-BP1 and pS6K, relative to actin control. b Western
blot analysis of PBL from 8 healthy subjects incubated with or
without Kyn at the indicated concentrations of 0.1, 0.5, and 1 mM for
24 h. C, Flow cytometry of intracellular pS6RP levels in CD4, CD8,
DN T-cell subsets of 8 healthy subjects. While top panels show
representative western blots (a, b) and flow cytometry dot plots (c),
bottom panels indicate cumulative analyses. *reflect p values\0.05
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CD8, CD25, and FoxP3. In accordance with previous find-
ings (Lai et al. 2012), mTOR was most elevated in DN T
cells relative to CD3?, CD4?, or CD8? T cells (p\ 0.001;
Fig. 7c) and CD4?CD25?FoxP3? Tregs (p\ 0.001; data
not shown). Kyn stimulated mTOR in DN T cells (Fig. 7c).
As a control amino acid of kynurenine metabolism, trypto-
phan (0.1, 1, and 10), which was neither accumulated in SLE
nor influenced by NAC, did not stimulate mTOR activity
(data not shown). Dibutyryl cAMP (db-cAMP), a cell-per-
meable derivative of cAMP, reduced mTOR activity in all
T-cell subsets (data not shown). Inhibition of mTOR by
cAMP was consistent with earlier findings (Xie et al. 2011).
4 Discussion
The present study reveals robust metabolome changes in
SLEwith amost prominent impact on the PPP. This pathway
supplies essential metabolites, R5P for nucleotide biosyn-
thesis and cell proliferation, and NADPH for antioxidant
defenses. The accumulation of S7P also implicates the PPP
in SLE, given that this metabolite is unique to this pathway
(Perl et al. 2011). S7P is a substrate of transaldolase (TAL),
and it is known to only accumulate in the deficiency of this
enzyme in mice (Perl et al. 2011; Hanczko et al. 2009) and
humans (Qian et al. 2008). The PPP is tightly linked to
cysteine metabolism and GSH homeostasis by providing
NADPH, which is essential for the regeneration of GSH
from its oxidized form, GSSG (Perl 2013) (Fig. 8). As
shown in this study, cysteine, which is the rate-limiting
factor of de novo GSH synthesis (Lu 2013), was profoundly
diminished in lupus PBL. Importantly, the loss of cysteine
was associated with the accumulation of its oxidized prod-
uct, cystine, as well as Met-SO (Haenold et al. 2008) and
HCA (Boldyrev 2009; Go and Jones 2011), all of which
represent metabolic evidence of oxidative stress in SLE.
While the depletion of cysteine and the accumulation of
cystine and Met-SO clearly indicate increased oxidative
stress in SLE, none of these compounds or the unique PPP
substrates R5P or S7P correlated with disease activity of
untreated patients. In contrast, metabolites connecting
multiple pathways, such as DHAP, common to both the PPP
and glycolysis, and OAA, common to the both TCA and
glycolysis, correlated with SLEDAI, BILAG, and FAS
scores, suggesting that increased flux among these pathways
are involved in disease activity.
As shown in this study, the prominent and NAC-
responsive accumulation of Kyn and its ability to activate
mTOR in DN T cells constitute a metabolic pathway of T
cell activation and lineage development in general. This
mechanism is particularly significant for lupus pathogene-
sis, given that DN T cells are a primary source of pro-
inflammatory IL-4, IL-17 and necrotic debris (Lai et al.
2013). The accumulation of Kyn may be a result of
decreased catabolism by Kyn hydroxylase owing to
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Fig. 8 Schematic diagram of the prominent metabolomic changes that
impact the pentose phosphate pathway (PPP) in patients with SLE. Red
and blue arrows mark the forward and reverse reactions in the PPP,
which are catalyzed by transaldolase (TAL), respectively (Perl et al.
2011). Metabolites are highlighted in red or blue, which reflects their
increase or decrease in lupus PBL. The PPP is connected with the
depletion of cysteine and the accumulation of homocysteic acid (HCA)
and kynurenine (Kyn). Therapeutic intervention with N-acetylcysteine
(NAC) reverses the accumulation of Kyn and the activation of mTOR,
which are thus considered redox-sensitive drivers of lupus pathogenesis
(Color figure online)
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Along these lines, NAC dramatically augmented the levels
of NADPH, which can occur through sparing of NADPH
via the enhancement of de novo GSH synthesis by NAC
(Perl et al. 2011; Hanczko et al. 2009). Thus, the marked
suppression of Kyn in NAC-treated patients can be attrib-
uted to the NADPH sparing effect of NAC (Hanczko et al.
2009). The reversal of HCA accumulation may represent a
direct effect of NAC on cysteine metabolism. By contrast,
NAC treatment did not reduce elevated levels of unique
PPP sugars, S7P and R5P, suggesting that altered PPP
activity lies upstream of GSH depletion in the order of
metabolic signaling defects in SLE. NAC also affected
other metabolic pathways that are centrally connected to
the PPP (Fig. 9). mTOR complex 1 (mTORC1), which was
measured here via phosphorylation of its downstream
substrate, pS6RP, is stimulated by oxidative stress (Sar-
bassov and Sabatini 2005) and the lysosomal accumulation
of amino acids (Bar-Peled et al. 2013). However, the
identity of specific amino acids that are sensed by
mTORC1 are presently unknown (Jewell et al. 2013).
Kynurenine has been recently linked to oxidative damage
in the eye (Linetsky et al. 2014). Therefore, the NAC-
responsive accumulation of Kyn may be particularly rele-
vant for understanding the fundamental biology of
mTORC1 activation by amino acids (Jewell et al. 2013)
under oxidative stress (Sarbassov and Sabatini 2005).
Tryptophan breakdown products, including Kyn, have been
found to possess both antioxidant (Gostner et al. 2015;
Grewal et al. 2014) and pro-oxidant properties (Linetsky
et al. 2014). Therefore, further studies are clearly warranted
to address the role of Kyn in oxidative stress of patients
with SLE.
In summary, this study documents profound changes in
the metabolome of lupus PBL with a dominant impact on
the PPP that reflects greater demand for nucleotides and
oxidative stress. The hereby discovered accumulation of
Kyn, which is metabolically linked to increased PPP
activity and responds to treatment with NAC, is identified
as potential contributor to mTOR activation in SLE.
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Fig. 9 Schematic interaction of
metabolomic changes in lupus
PBL via the PPP. Altered
compounds are identified by
standard KEGG codes and
acronyms in parentheses:
compounds in red indicate
metabolites with increased
levels in lupus PBL; compounds
in blue indicate metabolites with
reduced levels in lupus PBL;
compounds affected by NAC
treatment are highlighted in
yellow; compounds in black
indicate metabolites with
increased levels in lupus PBL
but not connected to the PPP.
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